H1 2023 Financial Highlights

Recently acquired medicines Г Г Bylvay (odevixibat) €23m TAZVERIK (tazemetostat) tablets 200 mg €19m Growth of 140%1 Strong momentum in North America and Europe Increasing number of treated PFIC patients Growth of 18% in commercial sales² Focus on all-comers, new-patient starts & duration of therapy Increasing share of office-based patients IPSEN Innovation for patient care All growth rates are at constant exchange rates. 1. Reference to Albireo's published H1 2022 performance. 2. Reference to Epizyme's published H1 2022 performance. PFIC: progressive familial intrahepatic cholestasis. 10 10

View entire presentation